Search company, investor...

BioNumerik Pharmaceuticals

bionumerik.com

Claim your profile to get in front of buyers, investors, and analysts.

Analyst Briefing Submitters are 7x more likely to receive a qualified connection. Learn more.

Total Raised

$74.83M

Investors Count

Deal Terms

Funding, Valuation & Revenue

6 Fundings

BioNumerik Pharmaceuticals's latest funding round was a Unattributed VC for $29M on December 5, 2003.

BioNumerik Pharmaceuticals's valuation in April 1996 was $33.64M.

Date	Round	Amount	Investors	Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.	Revenue	Sources
12/5/2003	Unattributed VC	$29M	AT&T, Access Venture Partners, Delta Capital Myanmar, Grelan Pharmaceutical, Southwest Venture Partners, and Woodside Fund		0 FY undefined
10/1/2000	Unattributed - II	$99M	Subscribe to see more		0 FY undefined	0
1/1/2000	Unattributed	$99M	Subscribe to see more		0 FY undefined	0
1/1/1998	Series D	$99M	Subscribe to see more		0 FY undefined	0
4/1/1996	Series B	$99M	Subscribe to see more	▲$33.64M	0 FY undefined	0

Date	12/5/2003	10/1/2000	1/1/2000	1/1/1998	4/1/1996
Round	Unattributed VC	Unattributed - II	Unattributed	Series D	Series B
Amount	$29M	$99M	$99M	$99M	$99M
Investors	AT&T, Access Venture Partners, Delta Capital Myanmar, Grelan Pharmaceutical, Southwest Venture Partners, and Woodside Fund	Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more
Valuation					▲$33.64M
Revenue	0 FY undefined	0 FY undefined	0 FY undefined	0 FY undefined	0 FY undefined
Sources		0	0	0	0

This profile has not been claimed.

You're more than your latest funding, tell our customers your company's story.

BioNumerik Pharmaceuticals Deal Terms

2 Deal Terms

BioNumerik Pharmaceuticals's deal structure is available for 2 funding rounds, including their Series B from April 01, 1996.

Round	Series B	Series A
Funding Date	$99M	$99M
Pre-Money Valuation
Post-Money Valuation
Amount Raised	$99M	$99M
Shares Authorized
Issuance Price
Dividend Rate
Liquidation Preferences
Liquidation Price
Participation
Conversion Price
Anti Dilution
General Voting	$99M	$99M
Board Voting	$99M	$99M
Par Value

Round	Funding Date	Pre-Money Valuation	Post-Money Valuation	Amount Raised	Shares Authorized	Issuance Price	Dividend Rate	Liquidation Preferences	Liquidation Price	Participation	Conversion Price	Anti Dilution	General Voting	Board Voting	Par Value
Series B	$99M			$99M									$99M	$99M
Series A	$99M			$99M									$99M	$99M